Patients in the UK will now be able to access advanced, personalized treatments prepared at the hospital or even in mobile ...

Swiss pharma Sandoz (SIX: SDZ) has spent less than a year charting its course as an independent company, but already it’s ...

Adding to the string of US and international drugmakers investment in US production investment following a call from ...

Shares in Replimune Group, a US biotech developing novel oncolytic immunotherapies, went in freefall Tuesday, as the company ...

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...

Canadian biotech Eyam Health has entered a research alliance with Swiss-based nonprofit Medicines for Malaria Venture to ...

Shares in Sarepta Therapeutics have slumped by more than a third since late last week amid new updates on its gene therapy ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

The US regulator has tapped Stanford University physician-scientist and former biotech executive George Tidmarsh to serve as ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

French pharma major Sanofi today announced it has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK.

Neuraxpharm Group, a privately-held German specialty pharma focused on central nervous system (CNS) disorders, today announced the launch of a new affiliate, Neuraxpharm Australia, led by newly ...